share_log

JMP Securities Initiates Coverage On CRISPR Therapeutics with Outperform Rating, Announces Price Target of $160

JMP Securities Initiates Coverage On CRISPR Therapeutics with Outperform Rating, Announces Price Target of $160

JMP证券以优于大盘的评级启动对CRISPR治疗药物的报道，宣布目标价为160美元
Benzinga Real-time News ·  2021/03/04 21:07

JMP Securities analyst Silvan Tuerkcan initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform rating and announces Price Target of $160.

JMP证券分析师Silvan Tuerkcan发起CRISPR治疗公司(纳斯达克：CRSP)，评级优于大盘，并宣布目标价为160美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发